subgroups of metastatic hormone-sensitive prostate cancer (mhspc)
Published 2 years ago • 271 plays • Length 2:25Download video MP4
Download video MP3
Similar videos
-
2:05
mhspc prognostic subgroups
-
2:18
arches: enzalutamide plus adt in mhspc subgroups
-
1:56
arasens: dialuramide plus adt and docetaxel for metastatic hormone-sensitive prostate cancer
-
3:51
metastatic hormone-sensitive prostate cancer (mhspc)
-
13:09
pca commentary: metastatic hormone sensitive prostate cancer (mhspc): many treatment options
-
1:17
treatment landscape for metastatic hormone-sensitive prostate cancer
-
1:35
arches: os by high or low disease volume and progression to mhspc or de novo mhspc
-
3:44
the evolving standard of care for patients with metastatic hormone-sensitive prostate cancer
-
2:10
current standards for first-line metastatic hormone-sensitive prostate cancer
-
4:05
evaluating triplet therapy in metastatic hormone sensitive prostate cancer
-
3:47
parp inhibitors for metastatic hormone sensitive prostate cancer
-
16:26
patient selection in metastatic hormone-sensitive prostate cancer (mhspc)
-
0:47
systemic triple therapy in metastatic hormone-sensitive prostate cancer
-
1:06:24
metastatic hormone sensitive prostate cancer
-
1:23
the evolving treatment landscape of mhspc and mcrpc
-
1:55
arches trial overview: adt plus enzalutamide for metastatic hormone-sensitive prostate cancer
-
1:01:45
metastatic hormone sensitive prostate cancer: expert guidance for urologists
-
17:44
new approaches to metastatic hormone sensitive prostate cancer
-
2:27
triplet therapy for metastatic hormone-sensitive prostate cancer